Exelixis, Inc. (EXEL) income statement
EXELNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends January 1
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Oct 2, 2026Last filing: 10-Q on Oct 29, 2026Score 18/305% above fair value
$68.29−0.21 (-0.31%)
Close on Nov 18, 2026Market cap $16.66BP/E 20.4Yield –
Exelixis, Inc. income statement
Ratios
Latest available, balances at Oct 2, 2026
Profitability, TTM
- Gross margin
- 96.3%
- Operating margin
- 40.2%
- Net margin
- 35.5%
- Return on equity, FY2025
- 35.5%
Financial strength
- Current ratio
- 3.21
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 74.0%
Valuation
- P/E ratio
- 20.4
- Price to sales
- 6.67
- Price to book
- 9.09
- Dividend yield
- –
See a number that looks wrong?